Bayer's Nubeqa one step closer to blockbuster status thanks to FDA priority review in potential new use

Aiming to make noise in oncology, Bayer is counting on prostate cancer drug Nubeqa as a potential blockbuster.

On Tuesday, the company took a step toward that goal, earning priority review status for the med in an indication that would broaden Nubeqa’s reach. Already approved for early-stage disease, Bayer’s label expansion bid centers on Nubeqa’s use against metastatic hormone-sensitive prostate cancer (mHSPC).